KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.315 $0.440 Thursday, 25th Apr 2024 GLMD stock ended at $0.393. This is 1.88% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 9.69% from a day low at $0.360 to a day high of $0.395.
90 days $0.300 $0.466
52 weeks $0.260 $5.63

Historical Galmed Pharmaceuticals Ltd. prices

Date Open High Low Close Volume
Oct 25, 2023 $0.360 $0.395 $0.360 $0.370 26 714
Oct 24, 2023 $0.370 $0.439 $0.370 $0.370 44 596
Oct 23, 2023 $0.430 $0.430 $0.390 $0.410 14 939
Oct 20, 2023 $0.431 $0.431 $0.415 $0.417 12 224
Oct 19, 2023 $0.427 $0.440 $0.410 $0.430 16 182
Oct 18, 2023 $0.428 $0.428 $0.405 $0.427 76 061
Oct 17, 2023 $0.410 $0.454 $0.380 $0.429 116 797
Oct 16, 2023 $0.410 $0.456 $0.400 $0.400 47 058
Oct 13, 2023 $0.438 $0.450 $0.410 $0.410 21 241
Oct 12, 2023 $0.450 $0.480 $0.450 $0.450 43 499
Oct 11, 2023 $0.460 $0.480 $0.422 $0.450 39 088
Oct 10, 2023 $0.440 $0.470 $0.432 $0.460 20 504
Oct 09, 2023 $0.450 $0.473 $0.420 $0.430 18 585
Oct 06, 2023 $0.450 $0.486 $0.446 $0.450 76 924
Oct 05, 2023 $0.450 $0.450 $0.431 $0.445 53 527
Oct 04, 2023 $0.460 $0.490 $0.366 $0.436 320 718
Oct 03, 2023 $0.533 $0.533 $0.445 $0.453 218 754
Oct 02, 2023 $0.600 $0.87 $0.500 $0.558 1 642 148
Sep 29, 2023 $0.576 $0.625 $0.570 $0.620 42 026
Sep 28, 2023 $0.565 $0.600 $0.540 $0.562 10 300
Sep 27, 2023 $0.582 $0.596 $0.550 $0.583 73 120
Sep 26, 2023 $0.578 $0.607 $0.538 $0.574 190 204
Sep 25, 2023 $0.631 $0.650 $0.581 $0.590 30 372
Sep 22, 2023 $0.639 $0.655 $0.613 $0.630 16 290
Sep 21, 2023 $0.669 $0.690 $0.600 $0.600 78 556
Click to get the best stock tips daily for free!

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica... GLMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT